Status:
COMPLETED
Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsies, Partial
Eligibility:
All Genders
16+ years
Phase:
PHASE2
PHASE3
Brief Summary
Subjects enrolled in the SP615, SP756, or SP774 open-label extension (OLE) trials receiving oral SPM 927 for at least 8 weeks and a stable dose of up to 3 antiepileptic medications may participate in ...
Eligibility Criteria
Inclusion
- Partial seizures with or without secondary generalization.
Exclusion
- Subject has previously received iv lacosamide.
- Subject meets the withdrawal criteria for the open-label extension trial.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00151879
Start Date
February 1 2005
End Date
May 1 2006
Last Update
September 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
RTP, North Carolina, United States